ABEONA THERAPEUTICS INC. (ABEO) - Dilution Analysis

10-Q filing | 56.6M shares outstanding

10-K filing | 53.0M shares outstanding

10-Q filing | 54.2M shares outstanding

10-Q filing | 52.5M shares outstanding

8-K filing: Abeona Therapeutics Inc. issued warrants to Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. to purchase up to an aggregate of 16,474 shares of Company common stock at an exercise price of $6.07 per share, with the warrants expiring on July 18, 2030.

10-Q filing | 49.8M shares outstanding

10-K filing | 48.5M shares outstanding

10-Q filing | 43.5M shares outstanding

10-Q filing | 40.0M shares outstanding

S-3/A filing: The filing is an S-3/A prospectus allowing the company to issue up to $300,000,000 of any combination of securities including common stock, preferred stock, warrants and/or debt securities and also covers an at the market offering of common stock having an aggregate offering price of up to $75,000,000 through Jefferies LLC.

S-3 filing: The filing is for a shelf offering of up to $300,000,000 of any combination of securities, including common stock and preferred stock. It also includes an at-the-market offering of common stock up to $75,000,000 through Jefferies LLC.

10-Q filing | 41.2M shares outstanding

8-K filing: Abeona Therapeutics Inc. entered into an underwriting agreement for the issuance and sale of 12,285,056 shares of common stock and pre-funded warrants to purchase 6,142,656 shares of common stock at $4.07 and $4.0699 respectively, in an underwritten offering, expected to close around May 7, 2024, with net proceeds estimated at $70.2 million.

10-K filing | 27.4M shares outstanding

8-K filing: Abeona Therapeutics Inc. entered into a Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. for up to $50 million in senior secured term loans; also issued warrants to purchase common stock to the lenders.

10-Q filing | 24.8M shares outstanding

10-Q filing | 24.8M shares outstanding

8-K filing: Abeona Therapeutics Inc. entered into a securities purchase agreement for the issuance and sale of 3,284,407 shares of common stock and pre-funded warrants to purchase 2,919,140 shares of common stock at $4.03 and $4.0299 per share/warrant respectively, with estimated net proceeds of $22.9 million.

10-Q filing | 16.9M shares outstanding

10-K filing | 17.7M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to 15,219,758 shares of the Company's Common Stock by selling stockholders.

10-Q filing | 17.2M shares outstanding

8-K filing: Abeona Therapeutics Inc. entered into a Securities Purchase Agreement for a private placement of common stock and warrants to investors, expecting to close on November 7, 2022. ($35.0M proceeds)

10-Q filing | 5.8M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 144,877,693 → 5,795,107

10-Q filing | 144.9M shares outstanding

8-K filing: Abeona Therapeutics Inc. entered into a Securities Purchase Agreement to issue preferred stock for gross proceeds of $25.0 million and intends to seek stockholder approval for a reverse stock split. ($25.0M proceeds)

10-K filing | 147.4M shares outstanding

8-K filing: The Company entered into an underwriting agreement to issue and sell 44,700,000 shares of common stock and warrants to purchase 44,700,000 shares of common stock at a combined price of $0.39 per share and warrant, with expected net proceeds of approximately $17.5 million before deducting underwriting discounts and commissions. ($0.0M proceeds)

10-Q filing | 101.9M shares outstanding

S-3/A filing: The company has filed an S-3/A form on 2021-10-19 registering common stock.

S-3/A filing: S-3/A filing related to the registration of common stock, potentially involving an underwriting agreement with indemnification clauses.

10-Q filing | 101.2M shares outstanding

S-3 filing: This S-3 filing registers an additional $250,000,000 of securities under a shelf registration, including unsold securities from a previous filing (File No. 333-224867).

10-Q filing | 99.0M shares outstanding

10-K filing | 98.8M shares outstanding

10-Q filing | 98.5M shares outstanding

10-Q filing | 84.8M shares outstanding

10-Q filing | 83.6M shares outstanding

10-K filing | 83.6M shares outstanding